These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10899164)

  • 1. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
    Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
    J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.
    Rothem L; Ifergan I; Kaufman Y; Priest DG; Jansen G; Assaraf YG
    Biochem J; 2002 Nov; 367(Pt 3):741-50. PubMed ID: 12139489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
    Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
    Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
    J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
    Dixon KH; Trepel JB; Eng SC; Cowan KH
    Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells.
    Drori S; Sprecher H; Shemer G; Jansen G; Goldman ID; Assaraf YG
    Eur J Biochem; 2000 Feb; 267(3):690-702. PubMed ID: 10651805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate.
    Zhao R; Assaraf YG; Goldman ID
    J Biol Chem; 1998 Apr; 273(14):7873-9. PubMed ID: 9525881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H; Takemura Y; Kobayashi H; Ando Y
    Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.
    Gifford AJ; Haber M; Witt TL; Whetstine JR; Taub JW; Matherly LH; Norris MD
    Leukemia; 2002 Dec; 16(12):2379-87. PubMed ID: 12454742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
    Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells.
    Dixon KH; Mulligan T; Chung KN; Elwood PC; Cowan KH
    J Biol Chem; 1992 Nov; 267(33):24140-7. PubMed ID: 1429743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
    Kobayashi H; Takemura Y; Ohnuma T
    Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
    Zhao R; Gao F; Hanscom M; Goldman ID
    Clin Cancer Res; 2004 Jan; 10(2):718-27. PubMed ID: 14760095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier.
    Zhao R; Gao F; Goldman ID
    Biochem Pharmacol; 1999 Nov; 58(10):1615-24. PubMed ID: 10535753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.